BioSpace News Archive

Longeveron Inc. today announced the selection of Biorasi LLC (“Biorasi”) as its clinical research organization (CRO) to help conduct its Phase 2 clinical trial evaluating Lomecel-B infusion in Alzheimer’s Disease (AD) subjects.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that the Centers for Medicare & Medicaid Services (“CMS”) will continue to provide increased Medicare reimbursement in the 340B outpatient hospital setting through year-end 2022 for 28 drugs, biologics and devices impacted by the COVID-19 public health emergency, including UDENYCA ® (pegfilgrastim-cbqv).

ThermoGenesis Holdings, Inc. today announced that the Company will release its financial results for the third quarter ended September 30, 2021 and provide a corporate strategic update on Friday, November 12, 2021, after the close of trading.

Thomas Scientific has finalized a five-year contract with Florida State University (FSU) as a strategic supplier of laboratory products and services.

Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA ® in Clinical Practice in the U.S.

Reven Holdings, Inc. today announced the publication of a peer-reviewed article in the prestigious medical journal Frontiers in Oncology.

Omeros Corporation (Nasdaq: OMER) today announced that the first report on urinary complement levels in kidney disease was presented yesterday at the Annual Meeting of the American Society of Nephrology.

Omeros Corporation (Nasdaq: OMER) today announced results of long-term follow-up from the Phase 2 clinical trial evaluating its MASP-2 inhibitor narsoplimab in patients with IgA nephropathy.

BriaCell Therapeutics Corp. announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board.

Delcath Systems, Inc. announced today it will host a comprehensive Investor Update event on Thursday, December 2 nd , from 10:00am ET – 1:00pm ET.